Form 10-Q - Quarterly report [Sections 13 or 15(d)]
SEC Accession No. 0001193125-26-347980
Filing Date
2026-08-13
Accepted
2026-08-13 08:30:38
Documents
83
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cadl-20260630.htm   iXBRL 10-Q 3309493
2 EX-10.2 cadl-ex10_2.htm EX-10.2 116694
3 EX-10.4 cadl-ex10_4.htm EX-10.4 26424
4 EX-31.1 cadl-ex31_1.htm EX-31.1 17030
5 EX-31.2 cadl-ex31_2.htm EX-31.2 17034
6 EX-32.1 cadl-ex32_1.htm EX-32.1 10061
7 EX-32.2 cadl-ex32_2.htm EX-32.2 10486
8 GRAPHIC img243075967_0.jpg GRAPHIC 30055
  Complete submission text file 0001193125-26-347980.txt   11207012

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20260630.xsd EX-101.SCH 1414493
87 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20260630_htm.xml XML 1782546
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 261270200
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)